The research focuses on two lipids with opposing biological effects: sphingosine-1-phosphate, commonly abbreviated S1P, and ceramide. Under the classical rheostat model proposed roughly 30 years ago, elevated S1P within a cancer cell promotes growth and survival, while higher concentrations of ceramide push the cell toward death. The analogy to a dimmer switch was apt in its original formulation: cancer cells were thought to adjust the relative levels of these two signaling molecules internally, tipping the balance toward uncontrolled division or, conversely, toward self-destruction. Generations of studies have been designed, and many experimental therapies conceived, on the assumption that this regulatory circuit was an intracellular affair.

The new findings upend that assumption. Using advanced spatial mapping technology applied to 574 human colon cancer tissue samples, the team discovered that as colorectal cancer progresses and spreads, levels of the pro-growth lipid S1P rise sharply while levels of the cell-killing lipid ceramide fall significantly. Crucially, however, the molecules responsible for producing S1P and for receiving its survival signals were not concentrated within the malignant cells. Instead, they clustered in the surrounding stromal tissue and in specialized immune cells, most notably macrophages, the scavenger cells that normally serve as first responders of the innate immune system. In other words, the chemical balancing act that determines whether tumors thrive appears to be orchestrated, in substantial part, by the neighborhood around the tumor rather than by the tumor itself.

This spatial redistribution has profound consequences for how metastatic colorectal cancer evades immunotherapy. According to the study, the accumulation of S1P signaling in the tumor microenvironment creates a state of chronic, unhealthy inflammation that effectively walls off cytotoxic T cells, the immune system’s primary tumor-killing weapons. The killer cells are prevented from getting close enough to the malignant cells to recognize and destroy them. Senior author Timothy J. Yeatman, MD, Professor of Surgery at the USF Health Morsani College of Medicine and associate center director for Translational Research and Innovation at the TGH Cancer Institute, framed the shift in thinking directly. For decades, he noted, researchers have thought of this pathway largely in terms of what happens inside the cancer cell and whether the cell survives or dies. What the new data suggest, he said, is that much of the important activity is actually happening in the neighborhood around the tumor, where it creates an environment that prevents the immune system from effectively attacking the cancer.

The technical details of the pathway add an important layer of specificity. The researchers identified the S1P receptor S1PR3 as a key mediator of the immunosuppressive effect. In the language of the paper, elevated S1P and its receptor S1PR3 act as a localized biochemical shield, driving out cytotoxic T cells and creating an immunosuppressive microenvironment. That characterization came from Siddabasave Gowda B. Gowda, Associate Professor at Hokkaido University’s Graduate School of Global Food Resources and Faculty of Health Sciences, who emphasized that targeting this pathway offers a therapeutic strategy to break these barriers, restore immune cell infiltration and potentially make immunotherapies effective for patients with advanced disease. The formulation is significant because it reframes immune evasion not as a passive absence of immune cells but as an actively constructed barrier, built from lipid signaling molecules secreted and sensed within the stromal compartment.

Beyond the lipid measurements, the team uncovered a three-gene signature that functions as a molecular warning sign of aggressive disease. High activity of this gene signature correlated strongly with late-stage cancer, with tumors that had spread into lymph nodes, with lower patient survival rates and with poor responses to standard checkpoint inhibitor immunotherapy. In practical terms, the signature could eventually help clinicians identify which metastatic colorectal cancer patients are least likely to benefit from existing immune therapies and might therefore be candidates for combination approaches that include pathway inhibition. The multiomics approach, integrating lipidomics, spatial transcriptomics and clinical outcome data across hundreds of patient samples, was essential to detecting these associations, since bulk tissue analysis would have averaged away the spatial information that proved decisive.

Laboratory experiments provided the functional proof of concept. When the researchers blocked two key components of the S1P signaling pathway, the effect on the immune landscape was striking: healthy killer T cells returned to the vicinity of the cancer cells and successfully attacked them again. This result demonstrates that the immunosuppressive state is not irreversible. It is maintained by ongoing signaling that can, at least in experimental settings, be interrupted. The authors caution that these are preclinical findings, but they support further investigation into whether pharmacological targeting of the pathway could remodel the immune environment surrounding a tumor and restore the effectiveness of immune-based treatments.

The clinical stakes are considerable. Colorectal cancer is the second-leading cause of cancer-related mortality worldwide, and the prognosis deteriorates dramatically once the disease metastasizes. Five-year survival rates drop to approximately 14 percent when colorectal cancer spreads to other parts of the body. Immune checkpoint inhibitors have transformed outcomes in several tumor types, including melanoma and certain lung cancers, but most metastatic colorectal tumors remain notoriously resistant to these drugs. Explaining that resistance has been a major clinical challenge, and the current study offers a mechanistic answer rooted in the tumor microenvironment rather than in the cancer cells’ own biology. If the S1P/S1PR3 axis can be therapeutically disabled, checkpoint inhibitors might gain the access they currently lack.

The study also carries conceptual weight for the broader field of cancer biology. The rheostat model has influenced how researchers interpret sphingolipid signaling across many cancer types, and the demonstration that a major component of that signaling is stromal and immune-mediated invites a re-examination of assumptions in other tumors as well. The authors describe their work as re-defining the sphingosine rheostat as a stromal-immune program, a phrase that signals a shift from a cell-autonomous view to an ecosystem view of tumor lipid biology. Such reframing matters because drugs designed to hit targets inside cancer cells may fail if the decisive biology resides in adjacent support tissue, a possibility that could help explain past therapeutic disappointments in this pathway.

Funding for the research came from the Tampa General Hospital Foundation, the National Cancer Institute through grants U01CA293474, R35CA197570 and P50CA236733, and the Japan Society for the Promotion of Science through KAKENHI grant 25K00258. The collaboration itself, spanning surgical oncology expertise in Tampa and lipid biochemistry in Hokkaido, reflects the increasingly international and multidisciplinary character of cancer microenvironment research. Whether S1P pathway inhibition can be translated into a safe and effective combination regimen for patients with metastatic colorectal cancer remains to be tested in clinical trials, but the study provides a clear molecular target, a biomarker signature for patient stratification and a mechanistic rationale for why the immune system, in so many of these patients, never gets the chance to fight.

Subject of Research: Sphingosine-1-phosphate signaling in the tumor microenvironment and immune evasion in metastatic colorectal cancer

Article Title: New study finds metastatic colorectal cancer’s immune defenses may begin outside the cancer cell, challenging view held for decades

Article References: New study finds metastatic colorectal cancer’s immune defenses may begin outside the cancer cell, challenging view held for decades. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: metastatic colorectal cancer, sphingosine-1-phosphate, S1PR3, ceramide, tumor microenvironment, macrophages, cytotoxic T cells, immunotherapy resistance, checkpoint inhibitors, spatial mapping, three-gene signature, sphingolipid signaling

The thymus is often dismissed as a vestigial organ, an immunological training camp that outlives its usefulness after childhood. Its involution, the gradual replacement of lymphoid tissue with fat, starts surprisingly early and proceeds throughout adult life. Yet the consequences of that decline have been hard to isolate. Recent work has sharpened the stakes considerably. A 2023 study in the New England Journal of Medicine found that adults who had their thymus removed faced elevated mortality and increased cancer risk, suggesting the organ keeps doing meaningful work long after puberty. Two companion papers in Nature in 2026 went further, linking poor thymic health in adults to higher cancer risk and, crucially, showing that preserved thymic health correlates with better outcomes after cancer immunotherapy. The new Nature Aging research now supplies a mechanistic bridge between those clinical observations and the cellular machinery of antitumor immunity.

The research team, led by Menzel and colleagues, focused on middle age—a window when the immune system is neither young nor elderly but is already undergoing measurable erosion. Their central discovery concerns naive CD8+ T cells, the uncommitted killer lymphocytes that have never encountered their target antigen. These cells are the raw material of cancer immunity: when a tumor sheds antigens, it is naive CD8+ T cells circulating through lymph nodes that are most likely to carry receptors capable of recognizing them. Once activated, they proliferate and differentiate into the cytotoxic cells that attack tumors. But the reservoir of naive cells is finite, and it is replenished almost exclusively by fresh output from the thymus. As thymic function fades, the reservoir drains and cannot easily be refilled.

What makes the new study particularly consequential is the sex bias it uncovered. In male mice, the loss of naive CD8+ T cells during middle age was markedly accelerated compared with females, and this decline triggered a physical contraction of the lymph nodes themselves. Lymph nodes are not passive containers; they are finely structured organs whose architecture supports the chance encounters between antigen-presenting cells and the rare T cells bearing matching receptors. When the nodes contract, the naive T cell pool within them thins out, and the probability that any given tumor antigen will find its cellular match drops. The researchers demonstrated that this anatomical shrinkage directly limited cancer antigen recognition in middle-aged male mice, providing a concrete structural explanation for a functional deficit.

The importance of rare tumor-reactive T cells has been highlighted by parallel work in the field. A 2026 study in Cell argued that stochasticity in cancer immunotherapy outcomes stems from rare but functionally critical T cell clones—the authors called them Spark T cells—whose abundance can determine whether an antitumor response ignites at all. Related work in Nature showed that rare, high-avidity CD8+ T cell clones residing in lymph nodes are critical for effective antitumor immunity, and that the PD-1 axis helps maintain these stem-like cells. Taken together with the new findings, a coherent picture emerges: immunotherapy success depends on a lottery in which scarce tumor-reactive clones must exist, survive, and be found. A contracted lymph node with a depleted naive pool stacks the odds against winning that lottery.

The sex difference is the element most likely to reverberate through clinical practice. Sex-based disparities in immune responses are well documented—females generally mount stronger humoral and cellular responses to infections and vaccines, while males show higher rates of many cancers. The new study suggests one mechanistic root of such disparities: faster thymic decline in males depletes the naive T cell compartment earlier, compromising the antigen-recognition step that precedes everything else in antitumor immunity. If the same dynamics hold in humans, middle-aged men may enter immunotherapy with a systematically smaller repertoire of tumor-reactive precursors, helping to explain why checkpoint inhibitors show variable and sometimes sex-skewed efficacy across patient populations. The supporting human data in the study, together with the epidemiological links between thymic health and immunotherapy outcomes, make this hypothesis testable in the clinic.

Perhaps the most exciting part of the work is what happened when the researchers intervened. Restoring thymic output in middle-aged male mice replenished the naive CD8+ T cell pool, reversed the lymph node contraction, and improved responses to immunotherapy. This is a proof of principle that the age-related immune deficit is not irreversible. Thymus regeneration, whether through pharmacological stimulation, hormone modulation, or other means of boosting T cell production, could in principle re-prime the immune system before or alongside checkpoint blockade, restoring the raw material that these drugs need in order to work. The finding reframes immunotherapy not just as a battle at the tumor site but as a supply-chain problem: the drugs unleash T cells, but only if enough of the right T cells exist to be unleashed.

The implications extend beyond oncology. The naive T cell pool underwrites responses to new infections, vaccines, and emerging pathogens throughout life. A contracting lymphoid infrastructure in middle age could help explain why vaccine efficacy wanes unevenly across age and sex, and why some adults respond poorly to novel antigens they have never encountered. The thymus, long treated as dispensable in adult medicine, may deserve a status closer to that of other endocrine organs whose gradual failure shapes disease risk. Measuring thymic output—through markers such as T cell receptor excision circles or recent thymic emigrants—could become a routine part of immunological risk assessment, much as bone density scans inform fracture risk.

Significant questions remain. Mouse models of aging and thymic involution do not map perfectly onto human biology, and the magnitude of the sex bias in humans is not yet established with the precision achieved in the animal experiments. It is also unclear how late in life thymic restoration remains feasible, and whether pharmacological approaches can safely boost thymic output without triggering autoimmunity, since the thymus is also the site where self-reactive T cells are deleted. Clinical trials will be needed to determine whether thymus-supporting interventions can genuinely improve immunotherapy outcomes, and which patient subgroups—by age, sex, and baseline thymic function—stand to benefit most.

Even with those caveats, the study marks a conceptual shift. For two decades, cancer immunotherapy has focused on removing the brakes on T cells already present in tumors. This work points upstream, to the production and housing of the naive cells from which antitumor responses are built. The image that lingers is of the lymph node as a shrinking library, its catalog of tumor-recognizing volumes thinning year by year, faster in males than in females. Rebuilding the library—by reviving the thymus that writes its books—may prove to be one of the most promising strategies for extending the reach of cancer immunotherapy to the patients it currently fails, particularly middle-aged men whose immune reserves are quietly running low.

Subject of Research: Sex-biased age-related decline of naive CD8+ T cells and its impact on antitumor immunity and immunotherapy response

Article Title: Naive T cell decline limits cancer immunity in middle-aged male mice

Article References: Naive T cell decline limits cancer immunity in middle-aged male mice. (2026). Nature Aging, 6(10), 2045–2046. https://doi.org/10.1038/s43587-026-01239-3 (Author names are not included in the publisher’s citation export.)

Image Credits: AI Generated

DOI: 10.1038/s43587-026-01239-3

Keywords: thymus, naive T cells, CD8+ T cells, lymph nodes, cancer immunotherapy, aging, immune senescence, thymic involution, antigen recognition, checkpoint inhibitors, sex differences, Nature Aging

The trial, known as FAB-HCC, enrolled twelve patients with advanced hepatocellular carcinoma who had progressed while receiving atezolizumab plus bevacizumab. The rationale rested on a growing body of evidence that the gut microbiome can act as a rheostat for the immune system, shaping how effectively checkpoint inhibitors unleash T cells against tumors. In cancers such as melanoma, earlier studies had shown that transferring fecal material from patients who responded to immunotherapy into those who did not could sometimes rekindle the anti-tumor response. The Vienna team extended this concept in two directions: they tested the approach in liver cancer, a tumor type arising in an organ intimately connected to the gut through the portal circulation, and they compared donors of two kinds, a patient with hepatocellular carcinoma who had responded robustly to anti-PD-1 therapy and a healthy individual.

Each participant received a single fecal microbiota transplantation via colonoscopy, followed by continued treatment with atezolizumab and bevacizumab. The primary endpoint of the study was safety, measured by the incidence and severity of treatment-related adverse events. This was a critical question, because both fecal transplants and the drug combination carry theoretical risks, particularly in patients with cirrhotic livers whose immune function is already compromised. The results were reassuring. The most frequent grade 3 or 4 treatment-related adverse events were arterial hypertension, seen in five patients, and proteinuria, seen in three, both of which are well-known toxicities of bevacizumab rather than consequences of the transplant. A single case of grade 3 diarrhea was attributed to the fecal microbiota transplantation itself. Importantly, no serious treatment-related adverse events were observed, and the procedure proved feasible in this vulnerable population.

The efficacy signals, while generated in a very small cohort, were eye-catching. Four of the twelve patients, an objective response rate of 33 percent, experienced radiologically confirmed tumor shrinkage after their disease had stopped responding to the same drug combination. The median progression-free survival was 6.9 months, with a 95 percent confidence interval spanning 3.0 to 10.8 months. For a population in which rechallenge with the same regimen would ordinarily be expected to yield little benefit, these numbers suggest that modulating the gut ecosystem may genuinely change the biological terrain on which immunotherapy operates. The authors are careful to frame the trial as hypothesis-generating, and with twelve participants, chance and selection effects cannot be excluded. Still, the consistency between the clinical outcomes and the molecular findings lends the results biological plausibility.

That plausibility comes from an unusually deep set of translational analyses. By sequencing microbial DNA from stool samples collected before and after the transplant, the researchers tracked whether the donor’s microbial community took up residence in the recipient, a phenomenon known as engraftment. After the procedure, the composition of the recipients’ gut microbiomes shifted toward that of their respective donors, indicating that a single colonoscopic delivery can durably alter the intestinal ecosystem. Notably, transplants from the healthy donor appeared to engraft more successfully than those from the responding patient, an observation with practical implications for how donor material might be selected in future trials. The team also documented a meaningful ecological shift in function: bacteria previously associated with immunotherapy response became enriched after the transplant, while deleterious species waned.

The immune consequences of this microbial remodeling were visible in the blood. Following the combined intervention, the number of circulating PD-1-positive CD8-positive T cells, a population often expanded in settings of chronic antigen stimulation and immune exhaustion, decreased. At the same time, a specific subset of monocytes, characterized by the marker CD32b and high expression of CD14 with low CD16, increased. Monocytes and their derivatives are increasingly recognized as key orchestrators of the tumor microenvironment, capable of either supporting or suppressing T-cell activity, and shifts in these populations may reflect a rebalancing of innate immunity toward a more inflammation-competent state. These cellular changes provide a mechanistic bridge between the microbial intervention and the clinical responses observed on imaging.

Perhaps the most novel analytical contribution came from an antibody-sequencing approach known as phage-display immunoprecipitation sequencing, which profiles the repertoire of antibodies circulating in a patient’s blood by measuring their binding to hundreds of thousands of synthetic peptide displays. Rather than finding that overall antibody diversity or composition predicted outcome, the researchers discovered that the stability of the antibody repertoire over time was what changed following the intervention. This suggests that the humoral immune system, the arm responsible for antibody production, undergoes a measurable recalibration when the gut ecosystem is reset and checkpoint blockade is resumed. It is a reminder that cancer immunotherapy responses are systemic events, rippling far beyond the tumor itself, and that tools capable of reading these ripples may eventually help identify which patients are responding long before scans can.

The study also carries a poignant human dimension. The responding patient who served as one of the donors represents a rare example of a cancer patient directly contributing biological material that may benefit others with the same disease. The trial was conducted at a single center with support from Roche, which supplied the investigational medicinal product, and it was registered under ClinicalTrials.gov identifier NCT05750030. The authors acknowledge with gratitude the contributions of patients, donors, and their families, as well as a statistician who contributed to the trial’s design and passed away before its completion, a quiet reminder of the human effort underlying every clinical dataset.

What happens next will determine whether this approach moves from promising pilot to standard of care. The central limitation is unmistakable: twelve patients, no control group, and an open-label design in which neither patients nor physicians were blinded to the intervention. Spontaneous fluctuations in hepatocellular carcinoma, and the possibility that simply continuing atezolizumab and bevacizumab after a treatment holiday benefits some patients, cannot be ruled out. Larger, adequately powered, ideally randomized trials will be needed to confirm that fecal microbiota transplantation genuinely reverses resistance rather than merely coinciding with it. If those trials succeed, the implications would extend well beyond liver cancer. The gut microbiome is already implicated in responses to checkpoint inhibitors across melanoma, lung cancer, and renal cell carcinoma, and a safe, single-procedure intervention that reprograms it could become a universal sensitizing strategy. For now, the Vienna results offer something oncology rarely enjoys after a treatment fails: a scientifically grounded reason to try again, delivered not with a new molecule but with the microscopic residents of a healthier gut.

Subject of Research: Fecal microbiota transplantation combined with atezolizumab-bevacizumab rechallenge in immunotherapy-refractory hepatocellular carcinoma

Article Title: FMT combined with atezolizumab-bevacizumab in hepatocellular carcinoma refractory to immunotherapy: an open label, single-arm, phase II pilot study

Article References: Pomej, K., Frick, A., Scheiner, B., Baumgartner, M., Schmetterer, K. G., Reyna-Blanco, C. S., Balcar, L., Pajancic, L., Kreuter, A., Séneca, J., Hausmann, B., Köcher, T., Prinzensteiner, M., Lampichler, K., Rohr-Udilova, N., Chakrabarty, A., Klotz, A., Lampl, A. C., Zinober, K., … Pinter, M. (2026). FMT combined with atezolizumab-bevacizumab in hepatocellular carcinoma refractory to immunotherapy: an open label, single-arm, phase II pilot study. Nature Communications. https://doi.org/10.1038/s41467-026-78219-z

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78219-z

Keywords: fecal microbiota transplantation, hepatocellular carcinoma, atezolizumab, bevacizumab, immunotherapy resistance, gut microbiome, checkpoint inhibitors, phase II pilot study, microbiome engraftment, PD-1, tumor immunology, Nature Communications

The study, published in the British Journal of Cancer, analyzed tumor specimens from 56 patients with newly diagnosed IDH-wildtype glioblastoma, the most common and most lethal molecular subtype of the disease. Rather than assuming all tumors look alike immunologically, the researchers first screened their cohort to identify cases with prominent intratumoral T-cell infiltration, a feature that only a fraction of glioblastomas display. In those T-cell-rich cases, they isolated CD3-positive, CD8-positive, CD4-negative cytotoxic T cells, the immune cells theoretically capable of killing tumor cells directly, and subjected them to single-cell RNA sequencing paired with T-cell receptor sequencing, a combination that reveals both what each cell is doing and what antigen specificity its receptor encodes.

The single-cell analysis produced a striking and consistent picture. Unsupervised clustering of the transcriptional data identified a dominant population of tumor-infiltrating lymphocytes defined by strong expression of exhaustion markers, with the checkpoint molecule LAG3 standing out as the most prominent. Exhaustion is a dysfunctional state that T cells enter after chronic antigen stimulation, in which they retain tumor recognition but lose much of their killing capacity. Critically, these exhausted cells also showed high T-cell receptor clonality, meaning the same receptor sequences appeared repeatedly across many cells. Clonal expansion of this kind is a classic hallmark of antigen-driven proliferation: it indicates that a specific stimulus, very plausibly tumor antigen, drove these cells to multiply within the tumor microenvironment.

To test whether this pattern was unique to their cohort or a general feature of glioblastoma, the team integrated their dataset with publicly available single-cell data from glioblastoma tumor-infiltrating lymphocytes and, as a comparative benchmark, with datasets from lung cancer TILs and malignant pleural effusions. The comparison revealed meaningful differences. Levels of LAG3 and of CXCL13, a chemokine that has emerged in recent years as a marker of tumor-reactive T cells in multiple cancer types, were significantly higher in the T-cell-rich glioblastoma subset from the Aichi Cancer Center cohort than in the public glioblastoma dataset. This suggests that T-cell infiltration in glioblastoma is not a uniform phenomenon but varies substantially between patients, and that the most infiltrated tumors contain a particularly pronounced exhausted, potentially tumor-specific compartment.

The most consequential step came next. The researchers applied an artificial intelligence-based prediction algorithm, developed with collaborators at NEC OncoImmunity, that estimates which T-cell receptors are likely to recognize tumor antigens based on sequence features and transcriptional context. When the algorithm was run across the datasets, it predicted that the T-cell-rich glioblastoma subset harbored a markedly higher proportion of potentially reactive T cells than either the public glioblastoma dataset or the lung cancer comparator samples. In other words, the exhausted, clonally expanded cells dominating these tumors are not merely bystanders or nonspecific inflammatory recruits; a substantial fraction of them may be genuinely tumor-reactive, held in check by their exhausted state.

These findings carry two major therapeutic implications. The first concerns LAG3, which has become one of the most closely watched immune checkpoint targets after PD-1 and CTLA-4. LAG3-blocking antibodies are already in late-stage clinical development for other cancers, and the new data provide a mechanistic rationale for testing LAG3-targeted approaches in glioblastoma, particularly in patients whose tumors show dense T-cell infiltration. If the potentially reactive T cells in these tumors are suppressed largely through LAG3-mediated inhibition, releasing that brake could reactivate a T-cell army that is already present and antigen-primed, a fundamentally different situation from trying to prime a response that does not exist.

The second implication involves antigen-specific immunotherapy, including personalized neoantigen vaccines and adoptive cell transfer. Previous work, such as the landmark neoantigen vaccine trial in glioblastoma led by researchers at Dana-Farber Cancer Institute, demonstrated that vaccine-induced T cells can traffic into these brain tumors, and other studies have shown that microbial peptides and aberrantly spliced tumor RNAs can generate antigens recognized by infiltrating lymphocytes. The new study adds a crucial piece to this puzzle by showing that in a subset of patients, the raw material for such approaches, clonally expanded, potentially tumor-reactive CD8 T cells, is already abundant. Identifying which patients fall into this T-cell-rich category could allow clinicians to select those most likely to benefit from vaccines, engineered T-cell therapies, or checkpoint blockade, moving glioblastoma immunotherapy toward a biomarker-driven strategy rather than a one-size-fits-all failure.

The study also refines the scientific understanding of T-cell exhaustion in brain tumors. Earlier single-cell analyses had described glioblastoma-infiltrating CD8 T cells as severely exhausted and had identified inhibitory receptors such as CD161 on glioma-infiltrating T cells, while other work characterized the dominant population as clonally expanded GZMK-positive effector cells. The new data reconcile these views by showing that exhaustion signatures in glioblastoma are not homogeneous: within the exhausted compartment, the clonally expanded, LAG3-high, CXCL13-positive subset is the one most likely to contain tumor-reactive cells. Distinguishing this potentially reactive exhausted state from generic dysfunction could guide the design of combination therapies that reinvigorate the right cells rather than broadly activating all T cells in the brain, where uncontrolled inflammation carries serious risks.

Important caveats remain. The prediction algorithm identifies candidate reactive T-cell receptors, but reactivity must ultimately be confirmed experimentally by identifying the antigens they recognize, and the proportion of truly tumor-specific cells among the predicted candidates is unknown. The T-cell-rich phenotype also applies to only a subset of the 56 patients studied, so the findings may not generalize to all glioblastomas. Nevertheless, the study provides a concrete foundation for two concrete therapeutic directions: antigen-specific approaches built on the T-cell receptors found in these tumors, and LAG-3-targeted immunotherapy aimed at releasing the brakes on cells that appear primed and waiting. For a disease whose median survival has barely moved in decades, the discovery that some glioblastomas already contain a recognizable, targetable immune response is a reason for cautious optimism, and a roadmap for the trials that must now follow.

Subject of Research: CD8+ tumor-infiltrating lymphocyte exhaustion signatures and potential tumor reactivity in glioblastoma

Article Title: Abundant CD8+ tumor-infiltrating lymphocytes in glioblastoma harbor distinct exhaustion signatures in potentially reactive subsets

Article References: Okamoto, T., Mizuta, R., Demachi-Okamura, A., Muraoka, D., Fukushima, Y., Ishihara, H., Sun, Y., Wang, Y., Nishida, R., Sasaki, E., Masago, K., Onoguchi, K., Tanaka, Y., Yamashita, Y., Stratford, R., Clancy, T., Muto, O., Tan, C. L., Otani, Y., … Matsushita, H. (2026). Abundant CD8+ tumor-infiltrating lymphocytes in glioblastoma harbor distinct exhaustion signatures in potentially reactive subsets. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03619-3

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03619-3

Keywords: glioblastoma, CD8 T cells, tumor-infiltrating lymphocytes, T-cell exhaustion, LAG3, CXCL13, single-cell RNA sequencing, T-cell receptor, immunotherapy, neoantigen, checkpoint inhibitors, brain cancer

The study, published in Cancer Immunology Research, a journal of the American Association for Cancer Research, tackles a question that immunologists have rarely been able to address directly in human tissue: does the way a T cell generates and uses energy determine whether it mounts an effective attack or slides into exhaustion? Exhaustion is a state in which a cell, activated too long and too continuously, stops responding to the threats it was designed to destroy. Checkpoint immunotherapy, such as antibodies against the PD-1 receptor, releases one of the brakes holding those cells back. For some patients the effect is dramatic; for many others it fails, and the reasons have remained stubbornly unclear.

Metabolism has long seemed a plausible place to look for answers. An immune cell’s capacity to act — to proliferate, to produce inflammatory signals, to kill tumor cells — is constrained by how it generates energy and building blocks. But probing that relationship in human tumors has been technically formidable. The standard laboratory method for measuring cellular metabolism requires a large, pure population of a single cell type, something that is nearly impossible to obtain from a biopsy. As first author Sujeetha A. Rajakumar, Ph.D., a former research associate in the Department of Otolaryngology–Head and Neck Surgery at Johns Hopkins Medicine, explains, what arrives from the clinic is a mixture, there is not much of it, and the cells researchers most want to study are often the rarest. Most of what the field knows about immune cell metabolism has therefore come from mouse tissue and cells grown in dishes, systems that do not always faithfully reflect what happens inside a patient.

The Johns Hopkins team circumvented this bottleneck by measuring each cell’s metabolic machinery alongside the surface markers that identify it. This approach allowed them to read three things from a single cell simultaneously: which cell type it is, what functional state it is in, and what metabolic profile it uses. They applied the method to several populations of tumor-infiltrating immune cells, including mucosal-associated invariant T (MAIT) cells, conventional CD8+ T cells, and innate lymphoid cells (ILCs). Because the technique works on scarce and mixed samples, it opened a window onto metabolic states that had previously been invisible in human tumor tissue.

The tumor samples came from patients enrolled in two phase II clinical trials at Johns Hopkins Medicine in which immunotherapy was administered before surgery. Participants received either the anti-PD-1 antibody nivolumab alone or nivolumab combined with an antibody against interleukin-8, a signaling protein that recruits immune cells to sites of inflammation and infection. Tissue was collected before immunotherapy began and again four weeks later at the time of surgery, giving the investigators a rare opportunity to observe how the immune and metabolic states of individual cells changed within the same patients over the course of treatment.

Three findings stood out. First, the team identified a population of T cells within these tumors that proved to be metabolically fitter and less exhausted than their neighbors, suggesting that not all tumor-infiltrating lymphocytes are equally depleted and that metabolic state tracks closely with function. Second, the more exhausted cells showed elevated levels of the enzyme glucose-6-phosphate dehydrogenase, or G6PD, the rate-limiting enzyme of a metabolic pathway those cells appear to rely on — making it a possible point of intervention. Third, a subset of innate lymphoid cells carried a metabolic profile associated with immune suppression, raising the possibility that these cells may actively pose an obstacle to checkpoint therapy rather than merely failing to help it.

To test whether the exhausted cells truly depend on the G6PD pathway, the researchers turned to laboratory cultures of tumor-infiltrating CD8+ T cells from a separate group of untreated patients. They sorted the cells according to their expression of CD39, a protein that can contribute to immunosuppression by limiting the activation of T cells. The cultures were then treated with a G6PD inhibitor, with an anti-PD-1 antibody, with both, or with neither. The combination treatment produced the largest gene expression changes in the most exhausted cells and increased their secretion of CD27, a marker of T-cell activation. In other words, the cells that seemed least reachable by conventional immunotherapy were the ones that changed the most when the metabolic pathway was blocked alongside checkpoint blockade.

Senior author Martin Alphonse, Ph.D., an assistant professor of dermatology at the Johns Hopkins University School of Medicine, frames the work around a deceptively simple question: take a piece of head and neck tumor tissue and you will find immune cells inside it whose sole purpose is to recognize something abnormal and destroy it — so what has happened to them? The answer emerging from this study is that part of what has happened is metabolic. Exhausted cells appear to have rewired their energy production in a way that can be mapped, and at least one node of that rewiring can be targeted in the laboratory to partially restore function. Rajakumar notes that when the pathway was blocked alongside checkpoint inhibitor treatment, the cells expected to be least reachable changed the most and became reactivated — evidence, she says, that the pathway is worth pursuing.

The clinical context makes the work consequential. Head and neck squamous cell carcinoma, which arises from the cells lining the mouth, throat and voicebox, is the seventh most common cancer worldwide, with roughly 890,000 new cases each year. With checkpoint inhibitors helping fewer than a quarter of these patients, any strategy that could expand the fraction of responders would address a major unmet need. Growing evidence has suggested that metabolic reprogramming influences whether a T cell mounts an effective response or becomes exhausted, but this study is among the relatively few to examine that link directly in human tumor tissue rather than in animal models or cell lines, and to do so across multiple immune cell types at single-cell resolution.

The researchers and their collaborators are careful to stress what the findings are and what they are not. Blocking G6PD in laboratory cultures reactivated exhausted cells, but no patient in the trials received a G6PD inhibitor, and the approach should not be considered a treatment itself. Alphonse emphasizes that these findings need confirmation in larger patient groups before anything can be built on them. The next steps, he says, are to reproduce the results in independent cohorts and to test whether interfering with this metabolic step has any effect in a living system, not just in a dish. Additional co-authors are Namya Nanda, Chloe Kim, Dustin Dikeman, Tanguy Y. Seiwert, Zubair Khan and Sewon Kang, all affiliated with Johns Hopkins Medicine. Study co-author Carole Fakhry, M.D., M.P.H., senior associate dean for clinical affairs at Johns Hopkins, underscores that such interdisciplinary, collaborative studies are critical to understanding how to make therapies more effective in the future, leveraging the translational capabilities of clinical trials to generate insights that laboratory work alone cannot provide. The work was supported by the Johns Hopkins Department of Dermatology, a Career Development Award from the Dermatology Foundation, the Department of Otolaryngology–Head and Neck Surgery, and the Bloomberg~Kimmel Institute for Cancer Immunotherapy. Alphonse and Rajakumar are inventors on two provisional patent applications related to the work, assigned to The Johns Hopkins University, which manages these relationships under its conflict-of-interest policies.

Subject of Research: Immunometabolic profiling of exhausted tumor-infiltrating T cells in head and neck squamous cell carcinoma

Article Title: Johns Hopkins investigators identify a metabolic weak point in exhausted immune cells in head and neck cancer

Article References: Johns Hopkins investigators identify a metabolic weak point in exhausted immune cells in head and neck cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: head and neck cancer, T cell exhaustion, immunotherapy, checkpoint inhibitors, G6PD, tumor metabolism, CD8+ T cells, innate lymphoid cells, MAIT cells, nivolumab, single-cell profiling, Cancer Immunology Research

The biological logic behind MSI-H/dMMR immunotherapy is the strongest in the field. When the mismatch repair machinery fails, cells accumulate insertion and deletion mutations that generate frameshift neoantigens, provoking a characteristic immune state: dense CD8-positive T-cell infiltration, heightened interferon signalling and adaptive upregulation of PD-1. Crucially, this immune phenotype is conserved across many tumour types, which is why pembrolizumab produced durable responses in roughly one-third of patients across more than 25 malignancies in the KEYNOTE-158 trial, with a median duration of response of 63.2 months. The paradigm extended beyond a single drug when the FDA granted accelerated approval to dostarlimab for previously treated recurrent or advanced dMMR solid tumours in 2021, supported by the GARNET study, in which the objective response rate reached 44 percent with responses lasting a median of 27.7 months. This, the authors argue, is what a genuine tumour-agnostic biomarker looks like: a shared, immune-sensitive biological state rather than a shared mutation.

Tumour mutational burden tells the opposite story. The premise was seductive: more mutations should yield more neoantigens and greater sensitivity to checkpoint blockade. But the pan-cancer experience exposed a fundamental flaw in that reasoning. A threshold of 10 mutations per megabase conflates biologically disparate cancers with different mutational processes, neoantigen quality, antigen-presentation machinery and immune microenvironments. TMB quantifies mutation burden while ignoring immunogenicity, T-cell infiltration and immune exclusion, all of which determine clinical response. In KEYNOTE-158, 102 patients with TMB-high tumours across ten histologies achieved an objective response rate of 29 percent, which was enough for the FDA’s 2020 accelerated approval of pembrolizumab for TMB-high solid tumours without satisfactory alternatives. Real-world datasets, however, show substantial heterogeneity by tumour type, with predictive value remaining strong mainly in cancers already characterised by immune infiltration. The immune ecosystem of a pancreatic adenocarcinoma differs fundamentally from that of a melanoma, regardless of whether a shared biomarker is present.

The review proposes that immunotherapy biomarkers be understood as layered rather than binary, spanning four domains. Tumour-intrinsic markers include MSI-H/dMMR, TMB, POLE and POLD1 mutations, viral antigens, DNA damage repair defects, mutational signatures and HLA loss. Immune microenvironment markers include PD-L1 expression, tumour-infiltrating lymphocytes, CD8 T-cell localisation, interferon signalling, myeloid infiltration and tertiary lymphoid structures. Host and systemic markers encompass immune fitness, microbiome composition, corticosteroid exposure and autoimmune risk, while dynamic markers include circulating tumour DNA kinetics, early radiographic patterns and immune-related toxicity. This layered model explains why single biomarkers perform inconsistently in tumour-agnostic practice. A high TMB result, for example, may be far less informative when it reflects treatment-induced hypermutation, such as temozolomide-associated hypermutation in recurrent glioma, rather than a clonal, endogenous immune-sensitive state.

The validation gap between candidate biomarkers is stark. PD-L1 protein expression has established tumour-specific assays and clinical utility, but its predictive value depends on the assay clone, scoring method, threshold and tumour lineage, and no PD-L1-expression-defined pan-cancer indication exists. PD-L1 gene amplification is rarer still, found in roughly 0.7 percent of tumours across more than 100 histologies in one pan-cancer series, and retrospective data suggest greater checkpoint inhibitor activity in amplified tumours, but no validated selection standard has emerged. Pathogenic POLE and POLD1 proofreading defects produce ultramutated, immunogenic phenotypes and correlate with checkpoint inhibitor efficacy, yet no regulatory indication rests on them alone, and the evidence is strongest in colorectal and endometrial cancers. Viral association, T-cell-inflamed gene signatures and tertiary lymphoid structures all carry biological plausibility and supportive evidence, but none constitutes a validated tumour-agnostic biomarker suitable for standalone prescribing.

Rare cancers expose the paradigm’s sharpest dilemma. Many are systematically excluded from pivotal trials yet demonstrate immunotherapy sensitivity without validated predictive biomarkers, as seen in Merkel cell carcinoma, alveolar soft-part sarcoma, thymic carcinoma and selected neuroendocrine subtypes. The SWOG S1609 DART trial, a phase 2 basket study of ipilimumab plus nivolumab across 53 rare cancer cohorts, enrolled 798 patients and confirmed responses in 24 of 53 cohorts, with an overall response rate of 13 percent and durable benefit in angiosarcoma, neuroendocrine tumours and rare gynaecological malignancies. The Australian MoST-CIRCUIT trial reported an objective response rate of 54 percent in advanced ovarian and endometrial clear cell cancers, most of which were mismatch repair-proficient and low TMB, and 63 percent in non-colorectal dMMR/MSI-H cancers across 17 tumour types. These results reveal immune-sensitive cohorts while leaving clinicians without biomarkers capable of identifying individual responders.

This is what the authors call the clinical grey zone: a patient with a rare cancer, exhausted standard options, emerging evidence of immunotherapy activity, no validated biomarker, no reimbursed molecular test and no feasible trial. A strictly biomarker-defined access model may be too restrictive, but unrestricted prescribing risks unwarranted toxicity, false hope and low-value care. The authors propose a pragmatic framework weighing four linked domains: strength of clinical evidence, biological and biomarker evidence within tumour-lineage context, competing treatment options, and patient-specific benefit-risk. Treatment can be recommended when convincing evidence or a validated immune-sensitive state exists and no superior option is available; considered with multidisciplinary review when uncertainty remains; and avoided outside a trial when evidence is absent, a superior therapy exists, or toxicity risk outweighs plausible benefit. The framework is deliberately not a numerical score, because strong evidence in one domain may override uncertainty in another.

Australia has become the world’s most consequential test case. In 2026, the Pharmaceutical Benefits Scheme consolidated and expanded public reimbursement of ipilimumab plus nivolumab and pembrolizumab for eligible patients with advanced or metastatic cancers considered immunotherapy-sensitive, including rare and uncommon cancers lacking conventional trial data. The listing, described as a world first and the product of partnership between government, industry, clinicians and patient advocates, includes shared costs between government and sponsor and a reassessment after three years. Critically, the reimbursement change did not create a corresponding tumour-agnostic regulatory indication, and the listing does not require a positive biomarker. Because broad pan-cancer next-generation sequencing is not universally funded in Australia, the country may be the first to fund pan-cancer immunotherapy without simultaneously funding the biomarker testing infrastructure needed to deploy it, transferring substantial selection responsibility to treating clinicians.

The economics of immunotherapy are also shifting. Annual treatment costs for PD-1 and PD-L1 inhibitors in the United States commonly exceed US$100,000 per patient, and multiple cost-effectiveness analyses have questioned the sustainability of broad population-level use at originator prices. Competition, biosimilar development and alternative procurement models may progressively reduce price as the sole determinant of access. As financial barriers ease, the question of appropriate use intensifies: severe immune-related adverse events occur in 15 to 20 percent of patients receiving checkpoint inhibitors, with fatal outcomes in 0.3 to 1.2 percent of cases. Reimbursement policy, the authors argue, cannot be considered independently of patient selection, and structured decision frameworks become the mechanism for translating genomic and immunologic data into responsible clinical guidance.

The lessons extend beyond checkpoint inhibitors to emerging pan-tumour platforms, including antibody-drug conjugates, bispecific antibodies and cellular therapies. Shared target expression among tumour types does not necessarily define a conserved therapeutic vulnerability: for antibody-drug conjugates, target density, internalisation kinetics, spatial heterogeneity, payload sensitivity and tumour lineage all influence efficacy despite expression of the same antigen. The review’s conclusion is measured but pointed. Tumour-agnostic immunotherapy has not made tumour type obsolete; it has shown that in selected settings biology can be more clinically informative than anatomy. Whether Australia’s experiment succeeds will depend on four prerequisites: funded molecular testing, expert decision support, prospective registries capturing outcomes and toxicity, and mechanisms for reassessment. Without those safeguards, the authors warn, the model risks both waste and harm, funding the drug before funding the pathway that decides who should receive it.

Subject of Research: Tumour-agnostic immunotherapy biomarkers and implementation of pan-cancer checkpoint inhibitor reimbursement

Article Title: Tumour-agnostic immunotherapy: aligning biological rationale, biomarker precision, and real-world implementation

Article References: Liu, J., Beal, J., Coleman, N., Lynam, J., & Subbiah, V. (2026). Tumour-agnostic immunotherapy: aligning biological rationale, biomarker precision, and real-world implementation. eClinicalMedicine, 100, Article 104211. https://doi.org/10.1016/j.eclinm.2026.104211

Image Credits: AI Generated

DOI: 10.1016/j.eclinm.2026.104211

Keywords: tumour-agnostic immunotherapy, MSI-H/dMMR, tumour mutational burden, checkpoint inhibitors, pembrolizumab, biomarkers, rare cancers, basket trials, Australia PBS reimbursement, precision oncology, tumour microenvironment, antibody-drug conjugates

The scale of the underlying problem gives the finding its urgency. According to GLOBOCAN 2022 estimates cited by the authors, esophageal cancer accounts for more than half a million new cases and more than 440,000 deaths annually, with incidence sharply concentrated in Asia where tobacco, alcohol, and nutritional risk factors compound the disease burden. For patients whose tumors are unresectable, recurrent, or metastatic, the historical standard of care, fluoropyrimidine or paclitaxel combined with platinum chemotherapy, has delivered only modest median survival and rarely durable control. That therapeutic ceiling created a strong biological rationale for moving immune checkpoint inhibition into the frontline, and ESCC proved an especially receptive target because it more often presents an inflamed tumor microenvironment and clinically relevant PD-L1 expression than esophageal adenocarcinoma.

Conducting a trustworthy synthesis across the new wave of trials, however, demanded unusual methodological care. The research team searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, and Web of Science from January 2015 through April 2025, following the PRISMA 2020 reporting framework. From 416 initial records, screening and full-text review narrowed the field to seven studies: six entered the primary pooled analysis and one, the biomarker-restricted ASTRUM-007 trial, was held back for sensitivity analysis because it enrolled only PD-L1-positive patients. A seventh candidate, GEMSTONE-304, was excluded outright because it tested PD-L1 blockade rather than PD-1 blockade, a distinction the authors treated as biologically meaningful rather than semantic.

The six primary trials form a who’s-who of modern esophageal oncology: KEYNOTE-590, from which only the prespecified squamous cell carcinoma subgroup was extracted to avoid contaminating the analysis with adenocarcinoma data; CheckMate-648, contributing its nivolumab-plus-chemotherapy arm; and the ESCORT-1st, JUPITER-06, ORIENT-15, and RATIONALE-306 studies, several of them conducted predominantly in China. Every single trial reported an overall survival advantage for the immunotherapy-containing regimen. Individual hazard ratios ranged from 0.58 for toripalimab plus paclitaxel and cisplatin in JUPITER-06 to 0.74 for nivolumab plus fluoropyrimidine and cisplatin in CheckMate-648, with pembrolizumab, camrelizumab, sintilimab, and tislelizumab regimens falling in between. When these estimates were combined using a fixed-effect inverse-variance model, the result was a hazard ratio of 0.68 with an I-squared statistic of zero percent.

That homogeneity statistic deserves attention because it is the technical heart of the paper’s credibility. I-squared quantifies what proportion of variability between study results is due to genuine differences rather than chance, with values above 75 percent conventionally labeled considerable heterogeneity. A value of zero across six trials testing five different PD-1 antibodies on multiple chemotherapy backbones, in populations spanning global and China-focused recruitment, suggests the survival benefit is a property of the drug class itself rather than an artifact of any single regimen or region. The authors nonetheless interpreted this cautiously, noting that I-squared loses precision when fewer than ten studies are pooled, and they ran random-effects and sensitivity analyses as robustness checks. Adding ASTRUM-007 changed nothing: the pooled estimate remained 0.68 with the same confidence interval, and the estimated between-study variance was zero.

The evidence quality assessment reinforced the headline result. Using the Cochrane RoB 2 tool, two independent reviewers judged five of the six primary trials at low overall risk of bias, with CheckMate-648 raising some concerns due to its open-label design and potential deviations from intended interventions. Under the GRADE framework, certainty for the overall survival outcome was rated high, reflecting phase III randomized data with consistent direction of effect, a precise pooled estimate, and minimal heterogeneity. Safety certainty was rated moderate because adverse-event definitions were not harmonized across trials, and certainty for biomarker-defined subgroups ranged from low to moderate owing to indirectness and imprecision.

That last point, biomarker interpretation, is where the analysis delivers its most clinically sobering nuance. The trials measured PD-L1 with fundamentally incompatible tools: some used the combined positive score, others tumor proportion score or tumor-area positivity, and several reported only exploratory analyses. Because quantitative pooling was impossible, the authors synthesized subgroup findings narratively, and the picture that emerges is one of attenuation at the biomarker-negative end. KEYNOTE-590 suggested diminished benefit in patients with CPS below 10, ORIENT-15 found no clear benefit in its small CPS-below-1 subgroup, and an external meta-analysis by Beshr and colleagues, incorporating CPS subgroup data presented at the September 2024 FDA Oncologic Drugs Advisory Committee meeting, similarly found no evident overall survival benefit in the CPS-below-1 population while benefit was greatest at CPS 10 or above. PD-L1, in other words, is not a universal binary gatekeeper, but the evidence base is weakest precisely where clinicians most need guidance: patients with low or negative expression.

Safety findings add a second layer of practical nuance. Grade 3 or higher treatment-related adverse events ranged from 47 to 72 percent in the immunotherapy arms and 36 to 68 percent in control arms, a reminder that platinum doublets are inherently toxic regardless of what is added to them. The distinctive contribution of PD-1 inhibitors is not a wholesale escalation of overall toxicity but the introduction of a new category of immune-mediated events, including hypothyroidism, rash, hepatitis, pneumonitis, and colitis. Most of these proved manageable with established treatment algorithms, but the authors emphasize that survival gains come with a corresponding obligation: earlier recognition of endocrine, pulmonary, hepatic, and gastrointestinal immune toxicities, multidisciplinary collaboration, and thorough patient education.

The clinical implications are direct. For fit patients with advanced or metastatic ESCC, the data support PD-1 inhibitor-based chemoimmunotherapy as a frontline standard, a position contemporary guidelines have already begun to reflect, though they differ in how strongly they tie specific agents to PD-L1 thresholds. The authors also caution that treatment choice should be contextualized by chemotherapy backbone, regulatory label, and local access, since the trials varied in these respects even as the relative effect remained constant. Notably, the revision corrects methodological flaws that have distorted earlier syntheses, avoiding mixed-histology overall estimates from KEYNOTE-590 and refusing to conflate CheckMate-648’s chemotherapy-free nivolumab-plus-ipilimumab arm with chemotherapy-containing regimens.

The study’s limitations are candidly acknowledged: it is a literature-based rather than individual-patient-data meta-analysis, biomarker subgroup reporting was too inconsistent for formal pooling, safety endpoints were synthesized narratively, and the review was not prospectively registered in PROSPERO. The authors also verified published journal corrections for at least two pivotal trial reports and confirmed no retractions among the key primary publications. What remains is a finding that will be difficult to dislodge: across every modern phase III trial conducted to date, adding a PD-1 inhibitor to frontline chemotherapy has extended survival in advanced esophageal squamous cell carcinoma, and the effect is as statistically uniform as oncology evidence rarely gets. The unfinished business is precision, determining which patients with minimal PD-L1 expression truly benefit, and ensuring that the assays used to measure that expression finally speak the same language.

Subject of Research: First-line PD-1 inhibitor-based chemoimmunotherapy versus chemotherapy alone for advanced or metastatic esophageal squamous cell carcinoma

Article Title: First‐Line PD‐1 Inhibitor‐Based Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Revised Systematic Review and Meta‐Analysis of Phase III Trials

Article References: Rothweiler, V., Roderburg, C., Koeksal, M., Jensen, B. E. O., Feldt, T., Gencer, I., Fischer, J. C., Budach, W., Knoefel, W. T., Lu, G., & Bölke, E. (2026). First‐Line PD ‐1 Inhibitor‐Based Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Revised Systematic Review and Meta‐Analysis of Phase III Trials. Cancer Reports, 9(9), Article e70660. https://doi.org/10.1002/cnr2.70660

Image Credits: AI Generated

DOI: 10.1002/cnr2.70660

Keywords: esophageal squamous cell carcinoma, PD-1 inhibitors, immunotherapy, meta-analysis, overall survival, PD-L1, phase III trials, chemoimmunotherapy, pembrolizumab, nivolumab, checkpoint inhibitors, GRADE certainty

The biological starting point is a mismatch between how tumors and immune cells process fuel. Most cancers exhibit the Warburg effect, a heavy reliance on aerobic glycolysis even in the presence of oxygen, which generates abundant lactate, promotes extracellular acidosis, and drives redox imbalance. This metabolic environment contributes to T-cell exhaustion, creating what the review describes as a negative feedback loop between tumor metabolic plasticity and immune suppression. Modern therapies, whether checkpoint inhibitors or cytotoxic drugs, often fail not because they cannot reach the tumor, but because the tumor’s metabolic adaptations and the immunosuppressive microenvironment they create blunt sustained responses.

The ketogenic diet intervenes by sharply reducing circulating glucose and insulin while raising ketone bodies, principally β-hydroxybutyrate and acetoacetate. For glycolysis-dependent tumor cells, this creates metabolic stress: glycolytic flux falls, lactate production drops, and the flow of glycolytic intermediates into the pentose phosphate pathway is restricted, depleting the nucleotide and NADPH pools needed for DNA synthesis and antioxidant defense. Ketogenic feeding also downregulates key glycolytic enzymes such as pyruvate kinase M2 and has been shown to increase mitochondrial reactive oxygen species in tumors. Cells already stressed by hypoxia, oncogenic signaling, or replication stress may then be pushed closer to the threshold at which chemotherapy- or radiation-induced damage becomes lethal.

Crucially, the review emphasizes that this selectivity is relative rather than absolute. Normal tissues and immune cells possess greater metabolic flexibility and can switch from glucose to fatty acid and ketone oxidation. Tumors with low levels of ketolysis enzymes, such as succinyl-CoA:3-ketoacid CoA transferase, cannot efficiently use β-hydroxybutyrate or acetoacetate as oxidative fuels and remain dependent on glycolytic substrates. Some tumors, however, retain functional ketolytic pathways and can adapt to ketosis, which limits the metabolic selectivity hypothesis. The diet’s benefits, the authors argue, are most likely in tumors that are highly glucose-dependent yet cannot compensate through ketone oxidation, and patient selection will therefore hinge on characterizing each tumor’s metabolic phenotype.

Ketone bodies are not merely fuel. β-hydroxybutyrate acts as a signalling metabolite with two notable functions: it engages the hydroxycarboxylic acid receptor 2 to dampen NF-κB and NLRP3 inflammasome-mediated inflammation, and it functions as an endogenous inhibitor of class I histone deacetylases, opening chromatin and altering transcriptional programs toward stress resistance and, in some contexts, anti-tumor states. Acetyl-CoA generated during ketolysis can feed into the citric acid cycle and support histone acetylation in immune cells, directly linking metabolism to gene expression. Experimental work shows that activated CD8-positive T cells can oxidize ketones to boost mitochondrial membrane potential and TCA-cycle flux, and that impairing ketone oxidation enzymes compromises T-cell proliferation and anti-tumor activity.

On the immune side, the diet may address one of the central barriers to durable immunotherapy responses: T-cell exhaustion. In the glucose-starved tumor microenvironment, activated T cells normally compete with glycolytic tumor cells and lose effector function. Under ketogenic conditions, metabolically flexible cytotoxic lymphocytes can sustain themselves through oxidative phosphorylation, and experimental studies suggest reductions in exhaustion markers such as PD-1, TIM-3, and LAG-3 in some settings. The diet may also re-polarize tumor-associated macrophages from immunosuppressive M2-like toward inflammatory M1-like phenotypes, and by lowering lactate and acidosis it may relieve metabolic suppression of dendritic cell antigen presentation. Effects on regulatory T cells are less predictable, since Treg maintenance depends on fatty acid oxidation and local nutrient composition, so ketosis may shift the nutrient competition between Tregs and effector CD8-positive cells rather than uniformly favoring one population.

These immunometabolic effects provide a mechanistic rationale for combining the diet with checkpoint inhibitors and adoptive cell therapies. Preclinical models have shown that ketogenic interventions can improve responses to PD-1 blockade, potentially converting immunologically cold tumors into more therapy-responsive states. For CAR-T therapy in solid tumors, where hypoxia, nutrient deprivation, and chronic antigen stimulation undermine engineered T-cell survival, ketogenic states could enhance oxidative metabolism and mitochondrial robustness, promoting memory-like T-cell states that sustain long-term responses. The review also explores synergy with targeted agents: reduced insulin and IGF-1 signaling may complement PI3K/Akt/mTOR inhibitors, and combinations with metformin or IDH inhibitors are biologically plausible, though evidence for clinically meaningful benefit remains preliminary.

A third layer of the framework involves the gut microbiome. By altering nutrient availability, the ketogenic diet changes microbial community composition and metabolite production, including short-chain fatty acids such as butyrate and propionate, which support epithelial barrier integrity, promote T-cell differentiation, and inhibit histone deacetylases. Certain bacterial taxa are associated with improved T-cell activation and better outcomes during anti-PD-1 therapy, raising the possibility that diet-induced microbiome remodeling could influence immunotherapy response. The authors stress, however, that direct proof linking ketogenic microbiome changes to improved cancer treatment outcomes remains preclinical, and connections between specific microbial shifts and therapy response have not been established as causal.

The clinical evidence base lags well behind the mechanistic story. Human studies to date, largely small prospective trials, pilot studies, and retrospective observations in glioblastoma, breast cancer, and gastrointestinal tumors, have consistently demonstrated that the diet reliably changes systemic metabolism, lowering glucose and insulin signaling and raising blood ketones when nutritional ketosis is achieved. Evidence for anti-tumor efficacy, however, is inconsistent, with some reports of disease stabilization and others showing no tumor control benefit. Adherence is a major obstacle, particularly in patients experiencing anorexia, nausea, or weight loss, and nutritional ketosis itself is a non-uniform exposure, with patients on ostensibly identical diets achieving different β-hydroxybutyrate levels. The review calls for future trials to report objective measures of ketosis, dietary composition, caloric and protein intake, and predefined metabolic targets, and to develop biomarker-guided approaches that identify which tumors are metabolically vulnerable.

The overarching message is one of calibrated optimism. The ketogenic diet should not be viewed as inherently anti-carcinogenic, nor as a substitute for established cancer therapies; current evidence does not support its use as an independent curative treatment. Instead, its greatest promise may lie in creating a coordinated biological environment, low glucose and insulin, elevated ketone signalling, preserved T-cell mitochondrial fitness, reduced dysfunctional inflammation, remodeled microbiome metabolites, and altered chromatin states, in which susceptible tumors become more sensitive to the therapies already in clinical use. Until large, controlled prospective trials clarify optimal patient selection, protocols, and long-term safety, the authors conclude, ketogenic strategies should remain carefully supervised adjunctive approaches within an emerging field of precision metabolic oncology.

Subject of Research: Ketogenic diet as an immunometabolic sensitization strategy in cancer therapy

Article Title: Ketogenic diet as a systems-level immunometabolic sensitization strategy in cancer therapy: integrating metabolism, immune reprogramming, microbiome dynamics, and epigenetic regulation

Article References: Mannan, M. S., Khan, M. W., Haseeb Khan, M. A., Javed, A., Hussain, S. M., & Adil, H. (2026). Ketogenic diet as a systems-level immunometabolic sensitization strategy in cancer therapy: integrating metabolism, immune reprogramming, microbiome dynamics, and epigenetic regulation. Medical Oncology, 43(11), Article 297. https://doi.org/10.1007/s12032-026-03425-0

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03425-0

Keywords: ketogenic diet, cancer metabolism, immunotherapy, beta-hydroxybutyrate, tumor microenvironment, gut microbiome, epigenetic regulation, T-cell exhaustion, Warburg effect, checkpoint inhibitors, nutritional ketosis, precision oncology

The enzyme in question is RNASET2, a ribonuclease best known for its role in antimicrobial defense. It chops up RNA derived from pathogens into small fragments that are subsequently detected by Toll-like receptors 7 and 8, sensors that help ignite innate immune responses. The clinical importance of this protein is underscored by a rare human condition: children born without functional RNASET2 develop cystic leukoencephalopathy, a brain disorder accompanied by elevated inflammatory markers in the cerebrospinal fluid and peripheral blood. Mice engineered to lack RNASET2 show a similar picture, with heightened expression of interferon-stimulated genes and neuroinflammation. All of this suggested that RNASET2 acts as a brake on innate immunity.

That brake, the Xiamen team reasoned, might be exactly what cancer cells exploit. Tumors routinely dampen innate immune signaling within themselves as a way of escaping immune surveillance, and any machinery that clears away danger signals could serve that purpose. The researchers therefore set out to determine whether RNASET2 contributes to this immune evasion, and whether releasing the brake could restore the tumor’s visibility to the immune system.

The danger signal RNASET2 clears is double-stranded RNA arising from the cell’s own genome. Mitochondria, the energy-producing organelles descended from ancient bacteria, continually transcribe their compact genomes, and the resulting mitochondrial double-stranded RNA can spill into the surrounding cytoplasm. Work over the past decade has established that this mitochondrial RNA is a potent trigger of innate immune pathways, and that cells must actively manage it to avoid chronic inflammation. RNASET2, the new study shows, is one of the managers: it degrades mitochondrial double-stranded RNA before it can accumulate and provoke a response.

The most striking twist in the study is chemical. RNASET2’s RNA-destroying activity is sensitive to magnesium, the abundant biological cation that sits at the heart of many enzymatic reactions. The researchers found that magnesium modulates the enzyme’s ability to clear double-stranded RNA, and that enhancing magnesium effectively inhibits RNASET2 function in this context. When RNASET2 is inhibited, mitochondrial double-stranded RNA builds up inside tumor cells, and that accumulation is not silent. The accumulating RNA trips innate immune sensors, driving the production of interferons and other inflammatory mediators that convert an immunologically cold tumor into an inflamed one.

That inflammatory conversion has direct consequences for therapy. Checkpoint inhibitors such as antibodies targeting PD-1 and PD-L1 work by releasing T cells from inhibition, but they depend on the tumor already being recognized as foreign. Tumors with high baseline innate immune signaling, often described as inflamed or hot tumors, respond far better than cold tumors that present no danger signals for T cells to act on. By forcing the accumulation of mitochondrial double-stranded RNA, RNASET2 inhibition manufactures exactly the inflammatory context that checkpoint blockade needs, and the study demonstrates that combining the two approaches boosts antitumor immunity in preclinical models.

The findings also reframe a familiar nutrient in a new light. Magnesium has long been appreciated as essential for T cell function; earlier work published in Cell in 2022 showed that magnesium is required for the proper function of cytotoxic T cells and that low magnesium environments impair their ability to kill infected or malignant cells. The new study adds a second, complementary mechanism: magnesium also shapes the innate immune landscape of the tumor itself by regulating an RNA clearance enzyme. A single ion thus influences both the effector arm of the immune response and the alarm signals that summon it, a convergence that may help explain why magnesium status correlates with cancer outcomes in epidemiological studies.

For the researchers, the path from basic enzymology to therapeutic strategy ran through a paradox. RNASET2 is, on balance, an anti-inflammatory protein, and one might expect that removing it would simply cause indiscriminate inflammation with little therapeutic benefit. Instead, the study shows that the inflammation generated by stalled RNA clearance is precisely targeted at the tumor, because it is the tumor’s own mitochondrial RNA that accumulates. This makes the intervention conceptually similar to other strategies that deliberately unleash self-derived nucleic acid sensing, such as inhibitors of TREX1 or STING agonists, but with a distinct molecular entry point and a simple dietary or pharmacological lever in the form of magnesium.

Considerable work remains before the approach could reach patients. The study is grounded in mouse models and mechanistic cell biology, and the therapeutic window will need careful definition: RNASET2 deficiency in humans causes a serious neuroinflammatory disease, so any clinical strategy must elevate RNA accumulation within tumors without reproducing systemic pathology. It is also not yet clear which tumor types, which dosing regimens of magnesium or RNASET2 inhibitors, and which combinations with existing immunotherapies would be optimal. The authors declare no competing interests, and the work was supported by the National Natural Science Foundation of China and related national programs, reflecting a sustained public investment in innate immunity research.

Even so, the study offers a memorable conceptual advance: the immune system’s alarm bells are not only rung and heard but actively muffled, and the muffling machinery can be switched off. If RNASET2 inhibition or magnesium-based approaches can be translated safely, a routine mineral could become an unlikely partner for the most sophisticated cancer drugs on the market, turning cold tumors hot by simply refusing to let them take out the trash.

Subject of Research: RNASET2-mediated clearance of mitochondrial double-stranded RNA and its inhibition to enhance cancer immunotherapy

Article Title: Inhibition of a magnesium-sensitive double-stranded RNA clearance machinery boosts cancer immunotherapy

Article References: Zhang, Z., Zhang, L., Luo, H., Huo, Y., Sun, B., Shi, J., Wu, S., Wang, P., & Wang, G. (2026). Inhibition of a magnesium-sensitive double-stranded RNA clearance machinery boosts cancer immunotherapy. Cell Research. https://doi.org/10.1038/s41422-026-01301-0

Image Credits: AI Generated

DOI: 10.1038/s41422-026-01301-0

Keywords: RNASET2, mitochondrial double-stranded RNA, cancer immunotherapy, innate immunity, magnesium, tumor immune evasion, interferon signaling, Toll-like receptors, checkpoint inhibitors, ribonuclease, tumor microenvironment, Cell Research

The review, led by Madlen Hörold of the Institute of Social Medicine and Health Systems Research at Otto von Guericke University Magdeburg together with colleagues from Regensburg, Halle, Dresden and other German centers, followed the Joanna Briggs Institute methodology for scoping reviews and reported according to the PRISMA-ScR checklist. The team searched MEDLINE, the Cochrane Library, Web of Science and CINAHL for studies published between January 2015 and March 2026, using a search strategy built on the PCC framework of Population, Concept and Context. After an initial sweep that yielded 2,862 records and a second, extended search adding 1,189 more, the researchers screened titles and abstracts independently, resolved disagreements through discussion with a supervisor, and supplemented the database results with manual screening of reference lists. From 2,993 references, 21 studies made the final cut.

Those 21 studies, published between 2016 and 2026, comprised thirteen quantitative investigations, three qualitative studies, three reviews and two mixed-methods papers. Geographically, the literature is heavily skewed: nine studies came from Australia, four from the United Kingdom, and the remainder from Denmark, Poland, the Netherlands and Iran. That concentration is not accidental. Australia and New Zealand carry the world’s highest melanoma burden, with an age-standardized incidence of 37.0 per 100,000 in 2022, compared with 30.6 in Norway and 16.5 in the United States. Intriguingly, despite those high rates, the review identified no randomized controlled trials of survivorship care from Norway or the USA, a gap the authors highlight as unexpected.

Within the included literature, the researchers identified seven distinct survivorship care programs: ASICA, which stands for Achieving Integrated Self-directed Cancer Aftercare for Melanoma; Mel-Self, which incorporated the ASICA intervention; Melanoma Care; MELACARE; MELCARE; CAPABLE; and a regional pilot program in Poland’s Lower Silesian Voivodeship. To organize what these programs actually deliver, the team applied the Cancer Survivorship Care Quality Framework, a structure developed by Nekhlyudov and colleagues that distinguishes five clinical domains from several contextual ones. The analysis, conducted as a qualitative content analysis following the Elo and Kyngäs methodology with the software MAXQDA 22, mapped each program’s components onto prevention and surveillance for recurrences and new cancers; surveillance and management of physical effects; surveillance and management of psychosocial effects; surveillance and management of chronic medical conditions; and health promotion and disease prevention.

The most heavily populated domain was recurrence surveillance, addressed by twelve studies. Here the review drew on work by Silverstein and colleagues, who summarized National Comprehensive Cancer Network guidance recommending skin and lymph node examinations every three to six months for two years after treatment, then every three to twelve months for a further three years, and annually thereafter as clinically indicated. Several programs push this surveillance toward the patient and the primary care system. Kamminga and colleagues discussed low-threshold skin checks and shifting recurrence monitoring to general practitioners, while digital, tablet-based interventions described in multiple studies support total skin self-examination at home, with images and data routed to a dermatology nurse practitioner for timely clinical response. The ASICA trials in the UK exemplify this approach, pairing structured self-examination training with personalized skin maps and nurse feedback.

Physical effects of modern therapy received attention in nine studies, and this is where the immunotherapy era creates genuinely new clinical demands. Silverstein and colleagues described screening and management of acute and chronic immune-related adverse events, including cardiovascular disease, inflammatory conditions, endocrinopathy and lymphedema, stressing that any new signs or symptoms appearing after immune checkpoint inhibitor therapy must be appropriately investigated. Kamminga and colleagues, in their qualitative work with oncology providers, framed the need for uniform and patient-driven oncological follow-up as one of four core concepts of survivorship care, adaptable to individual patient circumstances. Chronic condition management, however, was the thinnest domain of all: only a single article addressed it, recommending routine follow-up visits plus bloodwork every six to twelve months to catch late immune-related effects such as endocrinopathies, and involvement of subspecialty care when chronic conditions emerge during treatment.

Psychosocial care fared considerably better, appearing in twelve of the twenty-one studies. Reported interventions ranged widely: screening for anxiety, depression, sleep disturbances and financial toxicity; assessment of fertility impact and social support systems; monitoring of melanoma-specific health-related quality of life; and education in coping with fear of cancer recurrence using metacognitive strategies such as detached mindfulness and worry postponement. The MELACARE trial in Denmark combined nurse-led follow-up with skin self-examination training and fear-of-recurrence management for early-stage patients. Telephone-based psychotherapeutic sessions appeared in the Melanoma Care program, while older trials reviewed within the literature tested spiritually focused meditation, which produced less depression and more positive affect among metastatic melanoma patients, and telephone-based peer support, which patients found an acceptable substitute for face-to-face contact. Kamminga’s team argued that psychosocial problems should at minimum be identified through short questionnaires or patient-reported outcome measures, including work-related difficulties that patients often hesitate to raise in clinic.

Beyond the five clinical domains, the review mapped contextual features of the healthcare system that determine whether programs actually function. Eighteen articles addressed communication and decision making, describing personalized information combined with practical guidance, referral guides clarifying where to seek help, short educational videos, a psychoeducational booklet titled Melanoma: Questions and Answers, and communication channels spanning phone, email, SMS and Skype. Clinical structure was another recurring theme, with nurse-led follow-up in person or by telephone, scheduled appointments with plastic surgeons, medical coordinators, and health information systems including electronic medical records and telehealth. Care coordination, emphasized in five articles, emerged as a critical ingredient: survivorship care plans to facilitate follow-up, multidisciplinary teams that reduce patient uncertainty by giving a clear overview of next steps, a fixed contact person or case manager such as a clinical nurse specialist, and fast-tracked unscheduled clinic visits when a tele-dermatologist recommends them.

The review’s verdict is nuanced. The literature collectively covers all main areas of the Cancer Survivorship Care Quality Framework, but no single program covers all domains, and most studies focused on patients with stage 0 to IIc disease, leaving survivors of advanced melanoma comparatively underrepresented. Pilot randomized trials showed their concepts were feasible and acceptable, and survivorship care appears to reduce anxiety and depression, potentially improving quality of life, but the programs demand substantial investment in human and technological resources. Two empirical gaps stand out sharply: health literacy, where only the MELCARE program offered guidance on self-management strategies and online resources, and health economics, where no included study provided cost analyses. The authors argue that with a plethora of health information available and digital health applications proliferating, promoting patients’ health literacy should be a high priority. Their findings are intended to feed directly into the participatory development of a multimodal, patient-centered survivorship care program for people living with and beyond melanoma, funded by German Cancer Aid, with further research needed to confirm the effectiveness of survivorship care plans and to establish their economic case before widespread implementation.

Subject of Research: Survivorship care programs and follow-up needs of melanoma patients

Article Title: Survivorship care for melanoma patients: a scoping review

Article References: Hörold, M., Schutkowski, S., Drewitz, K.-P., Haferkamp, S., Schmitt, J., Meier, F., Bergmann, M., Küster, B., Pape, M., & Apfelbacher, C. (2026). Survivorship care for melanoma patients: a scoping review. Journal of Cancer Survivorship. https://doi.org/10.1007/s11764-026-02067-5

Image Credits: AI Generated

DOI: 10.1007/s11764-026-02067-5

Keywords: melanoma, cancer survivorship, scoping review, immunotherapy, checkpoint inhibitors, skin self-examination, psychosocial care, health literacy, nurse-led follow-up, telehealth, recurrence surveillance, survivorship care plans